×

MDxHealth(R): Completion of the acquisition of NovioGendix - New share capital amount and new number of shares

IRVINE, Calif. and HERSTAL, Belgium, Sept. 18, 2015 (GLOBE NEWSWIRE) -- MDxHealth SA (Euronext Brussels: MDXH) (the "Company") announced today that it succesfully completed the acquisition of all of the shares in NovioGendix Holding B.V. ("NovioGendix"). The acquisition of NovioGendix was announced on September 15, 2015 and the completion of the acquisition took place on September 18, 2015.

As part of the consideration that was paid for the shares in NovioGendix, the Company issued 1,086,956 new shares at an issue price of EUR 4.14 representing the average closing price of the Company's shares on Euronext Brussels during a period of 30 days ending on September 17, 2015.

In conformity with article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market, the Company announces that further to the issuance of the new shares, the Company's share capital was increased from € 35,097,093.09 to € 35,964,157.89, and its number of issued and outstanding shares was increased from 43,998,490 to 45,085,446 ordinary shares.

In addition to the outstanding shares, the total number of existing warrants (whether or not already granted or already vested) on the date of this press release amounts to 2,549,413 warrants which (if exercised) would entitle their holders to 2,678,565 shares with voting rights.

About MDxHealth®

MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

For more information:

Dr. Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info@mdxhealth.com
Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 7318 2955
Cell: +44 77 3965 8783
fennell@consilium-comms.com

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

To access the PDF version, click here http://hugin.info/137314/R/1953245/710747.pdf

HUG#1953245

Source: MdxHealth (TM)